Prognostic stratification of HPV-associated oropharyngeal cancer based on CD103+ immune cell abundance in patients treated on TROG 12.01 and De-ESCALaTE randomized trials
Authors:
- 4 May 2022
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 33 (8) , 804-813
Abstract
No abstract availableKeywords
Funding Information
- National Health and Medical Research Council
This publication has 19 references indexed in Scilit:
- Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trialThe Lancet, 2019
- Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trialThe Lancet, 2019
- Prognostic Significance of PD-L1+ and CD8+ Immune Cells in HPV+ Oropharyngeal Squamous Cell CarcinomaCancer Immunology Research, 2018
- Differences in T-cell infiltrates and survival between HPV+ and HPV- oropharyngeal squamous cell carcinomaFuture Science OA, 2016
- Stromal infiltration of CD8 T cells is associated with improved clinical outcome in HPV-positive oropharyngeal squamous carcinomaBritish Journal of Cancer, 2015
- Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancerBritish Journal of Cancer, 2013
- CD8+ and CD4+ tumour infiltrating lymphocytes in relation to human papillomavirus status and clinical outcome in tonsillar and base of tongue squamous cell carcinomaEuropean Journal of Cancer, 2013
- Human Papillomavirus and Survival of Patients with Oropharyngeal CancerNew England Journal of Medicine, 2010
- Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and NeckNew England Journal of Medicine, 2006
- Randomized Trial of Radiation Therapy Versus Concomitant Chemotherapy and Radiation Therapy for Advanced-Stage Oropharynx CarcinomaJNCI: Journal of the National Cancer Institute, 1999